Company Filing History:
5 out of 12,160 
1 out of 538 
1 out of 1 Years Active: 2002-2007
Title: Inventor Markus Albers: Pioneering Cytostatic Innovations
Introduction
Markus Albers, a distinguished inventor based in Leverkusen, Germany, has made significant contributions to the field of cytostatics, with a remarkable portfolio of 8 patents. His innovative work primarily revolves around enhancing the specificity and effectiveness of cancer treatments through targeted drug delivery systems.
Latest Patents
Among his most notable inventions are two recent patents that showcase his expertise in developing cytostatic conjugates linked to integrin ligands. The first invention involves cytostatic conjugates with integrin ligands, which link cytostatics to αβ-integrin antagonists using specific linking units that can be cleaved by elastase found in tumor tissue. This linkage ensures the stability of the cytostatic conjugate in biological fluids while enabling specific intracellular action within tumor cells. The second patent, integrin-mediated drug targeting, shares similar goals with a focus on serum stability and targeted release of the cytostatic within tumor cells through enzymatic or hydrolytic cleavability.
Career Highlights
Throughout his career, Albers has worked with prominent companies such as Bayer Aktiengesellschaft and Beiersdorf AG. His tenure at these organizations has provided him with invaluable experience in the pharmaceutical industry, driving his innovations in drug development and cancer treatment solutions.
Collaborations
Markus Albers has had the privilege of collaborating with esteemed colleagues including Klaus Urbahns and Andrea Vaupel. These partnerships have fostered an environment of shared knowledge and innovation, further enhancing the impact of his work in the field of medical research.
Conclusion
Markus Albers represents a vital force in the advancement of cancer treatment through his innovative patents and dedicated research efforts. His work exemplifies how targeted approaches in drug development can lead to more effective therapies, ultimately improving patient outcomes in the fight against cancer.